Latest Insider Transactions at Chimerix Inc (CMRX)
This section provides a real-time view of insider transactions for Chimerix Inc (CMRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of CHIMERIX INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of CHIMERIX INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 21
2025
|
Thomas J Riga COO and CCO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
60,828
-100.0%
|
$486,624
$8.55 P/Share
|
|
Apr 21
2025
|
Michael A. Sherman Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
233,413
-100.0%
|
$1,867,304
$8.55 P/Share
|
|
Apr 21
2025
|
Michael A. Sherman Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
189,995
-100.0%
|
$1,519,960
$8.55 P/Share
|
|
Apr 21
2025
|
David Jakeman VP OF FINANCE AND ACCOUNTING |
SELL
Sale (or disposition) back to the issuer
|
Direct |
156,209
-100.0%
|
$1,249,672
$8.55 P/Share
|
|
Apr 21
2025
|
Michelle La Spaluto CHIEF FINANCIAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
181,541
-100.0%
|
$1,452,328
$8.55 P/Share
|
|
Apr 21
2025
|
Allen S. Melemed CHIEF MEDICAL OFFICER |
SELL
Sale (or disposition) back to the issuer
|
Direct |
173,852
-100.0%
|
$1,390,816
$8.55 P/Share
|
|
Apr 21
2025
|
Robert J. Meyer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
35,150
-100.0%
|
$281,200
$8.55 P/Share
|
|
Apr 21
2025
|
Fred A Middleton |
SELL
Sale (or disposition) back to the issuer
|
Direct |
207,523
-100.0%
|
$1,660,184
$8.55 P/Share
|
|
Apr 21
2025
|
Fred A Middleton |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
3,407,954
-100.0%
|
$27,263,632
$8.55 P/Share
|
|
Apr 21
2025
|
Michael Albert Alrutz SVP AND GENERAL COUNSEL |
SELL
Sale (or disposition) back to the issuer
|
Direct |
216,689
-100.0%
|
$1,733,512
$8.55 P/Share
|
|
Apr 21
2025
|
Michael T. Andriole PRESIDENT AND CEO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
630,828
-100.0%
|
$5,046,624
$8.55 P/Share
|
|
Apr 21
2025
|
Martha J Demski |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
72,055
-100.0%
|
$576,440
$8.55 P/Share
|
|
Feb 13
2025
|
Allen S. Melemed CHIEF MEDICAL OFFICER |
SELL
Open market or private sale
|
Direct |
3,065
-1.97%
|
$12,260
$4.5 P/Share
|
|
Feb 13
2025
|
Michelle La Spaluto CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
2,260
-1.29%
|
$9,040
$4.51 P/Share
|
|
Feb 13
2025
|
David Jakeman VP OF FINANCE AND ACCOUNTING |
SELL
Open market or private sale
|
Direct |
300
-0.2%
|
$1,200
$4.53 P/Share
|
|
Feb 13
2025
|
Michael Albert Alrutz SVP AND GENERAL COUNSEL |
SELL
Open market or private sale
|
Direct |
1,600
-0.74%
|
$6,400
$4.52 P/Share
|
|
Feb 13
2025
|
Michael T. Andriole PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
7,370
-1.19%
|
$29,480
$4.52 P/Share
|
|
Jan 30
2025
|
David Jakeman VP OF FINANCE AND ACCOUNTING |
SELL
Open market or private sale
|
Direct |
2,800
-1.84%
|
$11,200
$4.1 P/Share
|
|
Jan 30
2025
|
Michael T. Andriole PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
2,350
-0.38%
|
$9,400
$4.1 P/Share
|
|
Jan 30
2025
|
Michelle La Spaluto CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,015
-0.58%
|
$4,060
$4.11 P/Share
|
|
Jan 07
2025
|
David Jakeman VP OF FINANCE AND ACCOUNTING |
BUY
Grant, award, or other acquisition
|
Direct |
10,855
+6.66%
|
-
|
|
Jan 07
2025
|
Allen S. Melemed CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
45,925
+22.75%
|
-
|
|
Jan 07
2025
|
Michelle La Spaluto CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
41,667
+19.12%
|
-
|
|
Jan 07
2025
|
Michael T. Andriole PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
150,000
+19.5%
|
-
|
|
Jan 07
2025
|
Michael Albert Alrutz SVP AND GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
41,667
+16.22%
|
-
|
|
Jan 07
2025
|
Thomas J Riga COO and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
54,275
+48.56%
|
-
|
|
Oct 28
2024
|
Fred A Middleton |
SELL
Bona fide gift
|
Indirect |
60,000
-60.0%
|
-
|
|
Aug 08
2024
|
Michael T. Andriole PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
1,285
-0.28%
|
$0
$0.83 P/Share
|
|
Feb 14
2024
|
David Jakeman VP OF FINANCE AND ACCOUNTING |
SELL
Open market or private sale
|
Direct |
2,660
-1.85%
|
$2,660
$1.04 P/Share
|
|
Feb 14
2024
|
Michelle La Spaluto CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,940
-1.72%
|
$1,940
$1.04 P/Share
|
|
Feb 14
2024
|
Michael T. Andriole PRESIDENT AND CEO |
SELL
Open market or private sale
|
Direct |
1,744
-0.39%
|
$1,744
$1.04 P/Share
|
|
Feb 01
2024
|
Michael Albert Alrutz SVP AND GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
21,875
+11.51%
|
-
|
|
Feb 01
2024
|
Michelle La Spaluto CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+18.12%
|
-
|
|
Feb 01
2024
|
Allen S. Melemed CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
28,125
+24.55%
|
-
|
|
Feb 01
2024
|
Michael T. Andriole PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
83,750
+15.73%
|
-
|
|
Feb 01
2024
|
David Jakeman VP OF FINANCE AND ACCOUNTING |
BUY
Grant, award, or other acquisition
|
Direct |
10,750
+6.95%
|
-
|
|
Dec 29
2023
|
Michael T. Andriole PRESIDENT AND CEO |
SELL
Bona fide gift
|
Direct |
17,000
-4.45%
|
-
|
|
Nov 17
2023
|
Fred A Middleton |
BUY
Open market or private purchase
|
Indirect |
17,295
+14.74%
|
$0
$0.96 P/Share
|
|
Nov 10
2023
|
Fred A Middleton |
BUY
Open market or private purchase
|
Indirect |
2,705
+3.17%
|
$0
$0.92 P/Share
|
|
Sep 28
2023
|
David Jakeman VP OF FINANCE AND ACCOUNTING |
SELL
Open market or private sale
|
Direct |
3,610
-2.64%
|
$0
$0.99 P/Share
|
|
Sep 25
2023
|
Fred A Middleton |
BUY
Open market or private purchase
|
Indirect |
20,000
+20.0%
|
$0
$0.98 P/Share
|
|
Aug 01
2023
|
Michael T. Andriole PRESIDENT AND CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,000
+6.14%
|
$25,000
$1.19 P/Share
|
|
May 18
2023
|
Michael T. Andriole PRESIDENT AND CEO |
BUY
Open market or private purchase
|
Direct |
51,700
+12.65%
|
$51,700
$1.14 P/Share
|
|
May 12
2023
|
Michael A. Sherman Chief Executive Officer |
BUY
Open market or private purchase
|
Indirect |
87,000
+48.15%
|
$87,000
$1.13 P/Share
|
|
May 10
2023
|
Martha J Demski |
BUY
Open market or private purchase
|
Indirect |
18,000
+19.99%
|
$18,000
$1.11 P/Share
|
|
May 08
2023
|
Robert J. Meyer |
BUY
Open market or private purchase
|
Direct |
8,750
+19.93%
|
$8,750
$1.14 P/Share
|
|
Mar 28
2023
|
Fred A Middleton |
BUY
Open market or private purchase
|
Indirect |
20,000
+25.0%
|
$20,000
$1.21 P/Share
|
|
Jan 26
2023
|
David Jakeman VP OF FINANCE AND ACCOUNTING |
SELL
Open market or private sale
|
Direct |
3,230
-2.31%
|
$3,230
$1.76 P/Share
|
|
Jan 17
2023
|
Michael Albert Alrutz SVP AND GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
21,450
+13.12%
|
-
|
|
Jan 17
2023
|
Michael A. Sherman Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
92,950
+29.42%
|
-
|